Prednisolone
A corticosteroid that suppresses inflammation. In two small trials in early schizophrenia, a six-week course did not clearly help.
At a glance
- Type
- Medicine: corticosteroid
- Used for
- Tested as an add-on to antipsychotics in recent-onset schizophrenia
- Status
- Experimental
- Evidence
- EarlyHow evidence is rated
- Administration
- Tablets, added to an antipsychotic. In the trials, a six-week course that started high and was reduced to zero
- Common side effects
- Higher blood sugar, a higher white blood cell count
- In Europe
- Tested in the Netherlands, Belgium, Denmark and Norway
Clinical summaryFor health professionals
- Nasib 2021 (Utrecht-led; Netherlands, Belgium, Denmark): 42 patients within 7 years of onset; prednisolone 40 mg a day, tapered to zero over 6 weeks, against placebo. PANSS improved equally in both groups. Stopped early for slow recruitment.
- NorPEPS (Norway, Hoprekstad 2025): the same regimen, 12 patients of 90 planned, stopped by COVID-19. No significant difference in PANSS total.
- Side effects in NorPEPS: raised fasting glucose and leukocytes; no worsening of psychosis or mania. Serious adverse events: 3, all on placebo.
What it is
Prednisolone is a corticosteroid, a synthetic form of a hormone the body makes to restrain inflammation. It acts broadly on the immune system and passes from the blood into the brain.1 It was tested in schizophrenia on the idea that inflammation contributes to the illness in some people.2
How well it works
A trial led from UMC Utrecht, with hospitals in the Netherlands, Belgium and Denmark, gave 42 people with schizophrenia that had begun within the previous seven years either a six-week course of prednisolone or a placebo, on top of their usual treatment. Symptoms improved in both groups to the same degree. The trial stopped early because recruitment was slow.2
A trial in Bergen, Stavanger and Trondheim used the same course. It planned to include 90 people but stopped after 12 because of the COVID-19 pandemic. Symptoms tended to improve more on prednisolone, but the difference was not clear enough to rule out chance.1
Across 70 trials of add-on treatments with possible anti-inflammatory effects, medicines designed to suppress inflammation did no better than the others.3
Side effects
In the Utrecht-led trial, no serious side effects occurred during treatment.2 In the Norwegian trial, blood sugar and the white blood cell count rose on prednisolone, psychotic and manic symptoms did not worsen, and the three serious adverse events all occurred on placebo.1
High doses of corticosteroids can bring on psychiatric symptoms.4 In autoimmune psychosis (opens in a new tab), where the immune system is the proven cause, they are part of the standard treatment.5
What we don’t know yet
- Whether a course of corticosteroids helps people with schizophrenia who have clear signs of inflammation.
